@article {2077, title = {Expressions of Matrix Metalloproteinase-3 and Tissue Inhibitor Metalloproteinase-1 in Corneal Tissue Post Alkali Burn Treated with Topical Medroxyprogesterone Acetate and Doxycycline}, journal = {Pharmacognosy Journal}, volume = {15}, year = {2023}, month = {August 2023}, pages = {553-557}, type = {Original Article }, chapter = {553}, abstract = {

Purpose: This study aims to investigate the effects of topical Medroxyprogesterone acetate (MPA) and Doxycycline in inhibiting the expression of MMP-3 and TIMP-1 in ocular alkali burn models in animals. Methods: A total of 18 New Zealand Rabbits were divided into 3 groups based on their post-alkali-burn treatment: PBS (G1/ control group), topical Doxycycline 1mg/ml (G2), and topical MPA 1\% (G3). Alkali burn models were made by exposing 1N NaOH solution to the central cornea for 30 seconds. MMP-3 and TIMP-1 expression were evaluated using immunohistochemistry after 14 days of treatment. Results: Statistically significant differences in the mean MMP-3 expression were found between the three groups (p=0.010). There was a significant difference in MMP-3 expression between the control group with MPA (p=0.017) and Doxycycline (p=0.028) but was not found between the MPA and Doxycycline groups (p=1,000). The mean differences in TIMP-1 expression between the three treatment groups were statistically significant (p=0.005), with a significant difference between the control group with Doxycycline (p=0.022) and MPA (p=0.007). There was no significant difference in TIMP-1 expression between the Doxycycline and MPA groups (P=1,000). Conclusion: This study indicated that topical administration of Doxycycline or MPA in ocular alkali burn reduces the expression of MMP-3 and TIMP-1.

}, keywords = {Corneal alkali burn, Doxycycline., Medroxyprogesterone acetate}, doi = {10.5530/pj.2023.15.118}, author = {Daya Banyu Bening and Reni Prastyani and Nurwasis and Evelyn Komaratih and Ismi Zuhria and Hari Basuki Notobroto and Dyah Fauziah and Chrismawan Ardianto} } @article {1932, title = {Relationship Histopathology Grading of Meningioma with the Use of Medroxyprogesterone Acetate (MPA) as A Hormonal Contraceptive}, journal = {Pharmacognosy Journal}, volume = {14}, year = {2022}, month = {January 2023}, pages = {938-941}, type = {Original Article }, chapter = {938}, abstract = {

Introduction: Meningioma is a common brain tumor with an incidence of more than 30\% of all primary brain tumors in adults. The incidence of meningiomas increases with increasing age, women suffer more from meningiomas with a ratio of 3:1. Meningiomas are known to have steroid receptors in the form of progesterone (88\%), estrogen (40\%), and androgen (40\%). Therefore, the use of hormonal therapy is suspected to affect the incidence and histopathological degree of meningioma. One of the widely used hormonal therapy is medroxyprogesterone acetate (MPA). However, there is not enough literature to explain the relationship between MPA and the incidence of meningioma. Objective: To identify the relationship between the duration of the use of Medroxyprogesterone acetate (MPA) hormonal contraceptives and the histopathological degree of meningioma. Methods: This study is an analytic observational with a retrospective design of meningiomas patients based on the duration of use of MPAtype hormonal contraception who performed surgery at Dr. Soetomo General Academic Hospital during the period January 2015 to December 2019. We determined the inclusion criteria for meningioma patients: a history of using MPA hormonal contraceptives or 3-month injectable contraceptives; and the control group: meningioma patients without a history of hormonal contraception. Results: There were 452 cases of meningioma and 101 patients met the inclusion criteria. Based on the results of statistical analysis, it was found that there was no difference relationship between the grade of meningioma and meningioma patients either using MPA or without using MPA. There was no difference in duration of use between the group using MPA \<10 years or more than 10 years with the non-hormonal control group on meningioma grading (p = 0.772). There was also no difference relationship between the group that did not use hormonal contraception and the MPA group on the age of the patient (p = 0.217), both using contraception for \<10 years and more than 10 years. Conclusion: There was no relationship found between histopathological degree of meningioma with the patients who use MPA contraceptives, both duration of use \<10 years and >=10 years compared with meningioma patients who do not use MPA contraception.

}, keywords = {Contraception, Grading, Hormonal contraceptive, Medroxyprogesterone acetate, Meningioma, MPA, Neoplasm., Progesterone}, doi = {10.5530/pj.2022.14.193}, author = {Shafhan Dustur and Joni Wahyuhadi and Budi Utomo and Muhammad Arifin Parenrengi and Abdul Hafid Bajamal and Sri Ratna Dwiningsih} }